Bladder urachal adenocarcinoma

Summary

Bladder urachal adenocarcinoma (MONDO:0004331) is a disease and 2 clinical trials. Top therapeutic interventions include cabozantinib, enfortumab vedotin, and ipilimumab. A subtype of urachus cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	bladder urachal adenocarcinoma
Mondo ID	MONDO:0004331
MeSH	C536474
DOID	DOID:7694
NCIT	C39843
UMLS	C2931201
MedGen	419014
GARD	0010186
Anatomy (UBERON)	UBERON:0002068
Is cancer (heuristic)	no

Also known as: adenocarcinoma of the urachus · bladder urachal adenocarcinoma · urachal adenocarcinoma · urachus adenocarcinoma

Data availability: 1 cell line.

Disease family

Classification path: disease › human disease › disease by body system or component › urinary system disorder › urinary bladder disorder › urinary bladder neoplasm › urinary bladder cancer › urachus cancer › bladder urachal adenocarcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03866382	PHASE2	RECRUITING	Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
NCT05756569	PHASE2	RECRUITING	Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CABOZANTINIB	4	3
ENFORTUMAB VEDOTIN	4	1
IPILIMUMAB	4	1